| Literature DB >> 32038721 |
Peng Zhang1,2, Jiafeng Wang3, Xiao Zhang4, Xiaolan Wang5, Liying Jiang6, Xuefeng Gu6.
Abstract
BACKGROUND: Kaposi sarcoma-associated herpes virus (KSHV) is one of the most common causal agents of Kaposi Sarcoma (KS) in individuals with HIV-infections. The virus has gained attention over the past few decades due to its remarkable pathogenic mechanisms. A group of genes, ORF71, ORF72, and ORF73, are expressed as polycistronic mRNAs and the functions of ORF71 and ORF72 in KSHV are already reported in the literature. However, the function of ORF73 has remained a mystery. The aim of this study is to conduct comprehensive exploratory experiments to clarify the role of ORF73 in KSHV pathology and discover markers of AIDS-associated KSHV-induced KS by bioinformatic approaches. METHODS ANDEntities:
Keywords: AIDS; ORF-73; herpesvirus; immune evasion; protein–protein interactions; sequence homology
Year: 2020 PMID: 32038721 PMCID: PMC6992650 DOI: 10.3389/fgene.2019.01376
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.599
GeneCards and UniPortKB databases used to choose the top-most scored identities of markers associated with KS.
| GeneCard database | ||||
|---|---|---|---|---|
| Sl. No | Symbol | Description | GC id | Score |
| 1 | KRT15 | Keratin 15 | GC17M039675 | 1.58 |
| 2 | OSM | Oncostatin M | GC22M030658 | 1.58 |
| 3 | TAT | Tyrosine aminotransferase | GC16M071599 | 1.27 |
| 4 | MKI67 | Marker of proliferation Ki-67 | GC10M129894 | 1.14 |
| 5 | CD34 | CD34 molecule | GC01M208057 | 1.11 |
| 6 | PTX3 | Pentraxin 3, long | GC03P157154 | 1.09 |
| 7 | PECAM1 | Platelet/endothelial cell adhesion molecule 1 | GC17M062399 | 1.01 |
| 8 | FLI1 | Fli-1 proto-oncogene, ETS transcription factor | GC11P128596 | 1.01 |
| 9 | IFNA2 | Interferon, alpha 2 | GC09M021374 | 1.01 |
| 10 | ACTC1 | Actin, alpha, cardiac muscle 1 | GC15M035080 | 0.99 |
| 1 | MIR1_HHV8P | E3 ubiquitin-protein ligase MIR1 | P90495 | K3 |
| 2 | MIR2_HHV8P | E3 ubiquitin-protein ligase MIR2 | P90489 | K5 |
| 3 | GB_HHV8P | Envelope glycoprotein B | F5HB81 | gBORF8 |
| 4 | ARBH_HHV8P | Apoptosis regulator Bcl-2 homolog | F5HGJ3 | vBCL2 ORF16 |
| 5 | SCAF_HHV8P | Capsid scaffolding protein | Q2HRB6 | ORF17 |
| 6 | OX2V_HHV8P | OX-2 membrane glycoprotein homolog | P0C788 | K14 |
| 7 | GN_HHV8P | Envelope glycoprotein N | F5HFQ0 | gN ORF53 |
| 8 | GM_HHV8P | Envelope glycoprotein M | F5HDD0 | gM ORF39 |
| 9 | ORF45_HHV8P | Protein ORF45 | F5HDE4 | ORF45 |
| 10 | VMI2_HHV8P | Viral macrophage inflammatory protein | Q98157 | ORF K4 |
| 11 | VIRF1_HHV8P | VIRF-1 | F5HF68 | vIRF-1 |
| 12 | ICP27_HHV8P | mRNA export factor ICP27 homolog | Q2HR75 | ORF57 |
| 13 | GH_HHV8P | Envelope glycoprotein H | F5HAK9 | gH ORF22 |
| 14 | AN_HHV8P | Shutoff alkaline exonuclease | Q2HR95 | ORF37 |
| 15 | LANA1_HHV8P | Protein LANA1 | Q9QR71 | LANA1 ORF73 |
Figure 1Conserved hypothetical protein domain of PHA03169 in reference to the ORF-73 of Human gamma herpesvirus 8,E-value 38e−18.
Figure 2Overview of the ORF-73 secondary structure prediction. The predicted structural positions incorporate two feed-forward neural networks obtained from PSI-BLAST.
Structure of Kaposi sarcoma marker ORF-73 predicted based on an environmental-specific substitution table and its structure-dependent gap penalties.
| Sl. No. | Profile Hit | PLEN | RAWS | RVN | ZSCORE |
|---|---|---|---|---|---|
| 1 | hs4blga | 121 | −755 | 247 | 24.21 |
| 2 |
| 191 | 215 | 8 | 17.29 |
| 3 |
| 136 | −822 | 10 | 16.57 |
| 4 |
| 323 | 249 | 21 | 14.78 |
| 5 |
| 188 | 157 | 33 | 14.61 |
| 6 |
| 351 | 325 | 115 | 13.67 |
| 7 |
| 93 | −880 | 5 | 13.53 |
| 8 |
| 103 | 168 | 19 | 13.45 |
| 9 |
| 156 | 166 | 6 | 13.28 |
| 10 |
| 396 | −555 | 5 | 12.92 |
PLEN, Profile length; RAWS, Raw alignment score; RVN, (Raw score)-(Raw score for NULL model); ZSCORE, Z-score normalized by sequence divergence (evolutionary relationship associated with a score >5.0 to the sequences are compared to each other); ZORI, Original Z-score (before normalization).
Figure 3Highest scored template c4k2jB chain B structure.
Figure 4Decameric ring structure of KSHV HHV-LANA DNA binding domain with dimensions (X:40.909, Y:43.389, and Z:44.674).
Figure 5The Kaposi sarcoma-associated herpesvirus infection pathway from KEGG. Reference pathway highlighted using red box shows that LANA is associated with p53 signaling pathway which confirms the predictable role of the ORF-73 protein in the KS associate marker protein.
Functional enrichment of p53.
| Biological process (GO) | ||||
|---|---|---|---|---|
| Sl. No | GO-term | Description | Count in gene set | False discovery rate |
| 1 | GO:0016579 | Protein deubiquitination | 10 of 275 | 3.83e−15 |
| 2 | GO:0007249 | I-kappaB kinase/NF-kappaB signaling | 8 of 70 | 3.83e−15 |
| 3 | GO:0035666 | TRIF-dependent toll-like receptor signaling pathway | 6 of 24 | 8.43e−13 |
| 4 | GO:0051092 | Positive regulation of NF-kappaB transcription factor activity | 5 of 2142 | 6.64e−11 |
| 5 | GO:0070423 | Nucleotide-binding oligomerization domain | 5 of 27 | 4.65e−10 |
| Molecular function (GO) | ||||
| 1 | GO:0031625 | Ubiquitin protein ligase binding | 5 of 311 | 4.44e−05 |
| 2 | GO:0042975 | Peroxisome proliferator activated receptor binding | 2 of 10 | 0.00062 |
| 3 | GO:0019899 | Enzyme binding | 7 of 2197 | 0.0012 |
| 4 | GO:0042802 | Identical protein binding | 6 of 1754 | 0.0032 |
| 5 | GO:0032813 | Tumor necrosis factor receptor superfamily binding | 2 of 46 | 0.0052 |
| Cellular components (GO) | ||||
| 1 | GO:0043657 | Host cell | 4 of 29 | 2.76e−07 |
| 2 | GO:0030666 | Endocytic vesicle membrane | 5 of 152 | 2.90e−07 |
| 3 | GO:0098805 | Whole membrane | 8 of 1554 | 3.85e−06 |
| 4 | GO:0012506 | Vesicle membrane | 6 of 743 | 1.69e−05 |
| 5 | GO:0005741 | Mitochondrial outer membrane | 4 of 181 | 3.05e−05 |
| KEGG pathway | ||||
| 1 | hsa04668 | TNF signaling pathway | 4 of 108 | 1.27e−05 |
| 2 | hsa04064 | NF-kappa B signaling pathway | 4 of 93 | 1.27e−05 |
| 3 | hsa05160 | Hepatitis C | 4 of 131 | 1.60e−05 |
| 4 | hsa04210 | Apoptosis | 4 of 135 | 1.60e−05 |
| 5 | hsa05167 | Kaposi's sarcoma-associated herpesvirus infection | 4 of 183 | 3.53e−05 |
| Reactome pathways | ||||
| 1 | HSA-5357956 | TNFR1-induced NFkappaB signaling pathway | 9 of 30 | 3.98e−21 |
| 2 | HSA-5357905 | Regulation of TNFR1 signaling | 9 of 32 | 3.98e−21 |
| 3 | HSA-5689880 | Ub-specific processing proteases | 10 of 202 | 1.94e−17 |
| 4 | HSA-6804757 | Regulation of TP53 Degradation | 7 of 35 | 2.30e−15 |
| 5 | HSA-5675482 | Regulation of necroptotic cell death | 6 of 17 | 2.63e−14 |
| UniPort keywords | ||||
| 1 | KW-0832 | Ubl conjugation | 9 of 2380 | 1.28e−05 |
| 2 | KW-0013 | ADP-ribosylation | 4 of 100 | 1.28e−05 |
| 3 | KW-1017 | Isopeptide bond | 7 of 1713 | 0.00017 |
| 4 | KW-0945 | Host–virus interaction | 4 of 432 | 0.00094 |
| 5 | KW-0963 | Cytoplasm | 9 of 4972 | 0.0015 |
| PFAM Protein Domains | ||||
| 1 | PF14560 | Ubiquitin-like domain | 4 of 14 | 3.12e−09 |
| 2 | PF11976 | Ubiquitin-2 like Rad60 SUMO-like | 4 of 21 | 6.44e−09 |
| 3 | PF00240 | Ubiquitin family | 4 of 46 | 7.76e−08 |
| 4 | PF02201 | SWIB/MDM2 domain | 2 of 5 | 2.86e−05 |
| 5 | PF00641 | Zn-finger in Ran binding protein and others | 2 of 16 | 0.00017 |
| INTERPRO Protein Domains and Features | ||||
| 1 | IPR019956 | Ubiquitin | 4 of 12 | 1.83e−09 |
| 2 | IPR019954 | Ubiquitin conserved site | 4 of 10 | 1.83e−09 |
| 3 | IPR000626 | Ubiquitin domain | 4 of 57 | 3.14e−07 |
| 4 | IPR016495 | p53 negative regulator Mdm2/Mdm4 | 2 of 2 | 1.46e−05 |
| 5 | IPR029071 | Ubiquitin-like domain superfamily | 4 of 184 | 1.75e−05 |
| SMART Protein Domains | ||||
| 1 | SM00213 | Ubiquitin homologues | 4 of 45 | 6.77e−08 |
| 2 | SM00005 | DEATH domain, found in proteins involved in cell death | 2 of 27 | 0.00035 |
| 3 | SM00184 | Ring finger | 3 of 308 | 0.0012 |
Figure 6Protein–protein interactions (PPI) between cell arrest marker p53 of cancer cell and Ubiquitin Specific Peptidase 2 (USP2). TNF receptor-associated factor 2 (TRAF2), tumor necrosis factor receptor superfamily member 1A (TNFRSF1A), polyubiquitin-C (UBC), protein Mdm4, E3 ubiquitin-protein ligase Mdm2, ubiquitin-40S ribosomal protein S27a, polyubiquitin-B (UBB), NF-kappa-B essential modulator (IKBKG), receptor-interacting serine/threonine–protein kinase 1 (RIPK1), and Ubiquitin-60S ribosomal protein L40 (UBA52) play important roles in the regulation of cell survival and apoptosis.
Figure 7(A) Tumor protein 53 (TP53) network analysis and (B) members of the complex pathway and genes with co-expression, co-localization, genetic interactions and specific functions.
Figure 8Network map of KEGG for the selected KS protein marker LANA. Protein downstream effect in the cell cycle of disease progression with pooled effectors in cell cycle arrest at G1/S and KS activating mechanisms.
Identities of associated markers, downstream signaling candidates, and linked pathways during Kaposi sarcoma pathogenesis.
| Sl. No | Entry | Description |
|---|---|---|
| 1 | N00216 | HGF-MET-RAS-ERK signaling pathway |
| 2 | N00160 | KSHV K1 to RAS-ERK signaling pathway |
| 3 | N00188 | IL1-IL1R-JNK signaling pathway |
| 4 | N00189 | KSHV K15 to JNK signaling pathway |
| 5 | N00186 | IL1-IL1R-p38 signaling pathway |
| 6 | N00187 | KSHV Kaposin B to p38 signaling pathway |
| 7 | N00182 | IGF-IGFR-PI3K-NFKB signaling pathway |
| 8 | N00179 | KSHV K1 to PI3K-NFKB signaling pathway |
| 9 | N00030 | EGF-EGFR-RAS-PI3K signaling pathway |
| 10 | N00159 | KSHV K1 to PI3K signaling pathway |
| 11 | N00056 | Wnt signaling pathway |
| 12 | N00175 | KSHV LANA to Wnt signaling pathway |
| 13 | N00053 | Cytokine-Jak-STAT signaling pathway |
| 14 | N00181 | KSHV vIL-6 to Jak-STAT signaling pathway |
| 15 | N00147 | EGF-EGFR-PLCG-calcineurin signaling pathway |
| 16 | N00180 | KSHV K1 to PLCG-calcineurin signaling pathway |
| 17 | N00172 | KSHV K15 to PLCG-calcineurin signaling pathway |
| 18 | N00148 | TLR3-IRF7 signaling pathway |
| 19 | N00162 | KSHV vIRF3 to TLR3-IRF7 signaling pathway |
| 20 | N00163 | KSHV KIE1/2 to TLR3-IRF7 signaling pathway |
| 21 | N00149 | TLR3-IRF3 signaling pathway |
| 22 | N00161 | KSHV vIRF1/2 to TLR3-IRF3 signaling pathway |
| 23 | N00463 | Alternative pathway of complement activation |
| 24 | N00213 | KSHV Kaposin to alternative pathway of complement activation |
| 25 | N00150 | Type I IFN signaling pathway |
| 26 | N00261 | KSHV vIRF2 to IFN signaling pathway |
| 27 | N00151 | TNF-NFKB signaling pathway |
| 28 | N00174 | KSHV vFLIP to TNF-NFKB signaling pathway |
| 29 | N00173 | KSHV K15 to TNF-NFKB signaling pathway |
| 30 | N00171 | KSHV vFLIP to NFKB signaling pathway |
| 31 | N00152 | CXCR-GNB/G-ERK signaling pathway |
| 32 | N00157 | KSHV vGPCR to GNB/G-ERK signaling pathway |
| 33 | N00153 | CCR/CXCR-GNB/G-PI3K-RAC signaling pathway |
| 34 | N00462 | KSHV vCCL1/2/3 to CCR signaling pathway |
| 35 | N00212 | KSHV vCCL2 to CCR signaling pathway |
| 36 | N00178 | KSHV vGPCR to GNB/G-PI3K-JNK signaling pathway |
| 37 | N00154 | CXCR-GNB/G-PI3K-AKT signaling pathway |
| 38 | N00158 | KSHV vGPCR to GNB/G-PI3K-AKT signaling pathway |
| 39 | N00363 | Antigen processing and presentation by MHC class I molecules |
| 40 | N00184 | KSHV MIR1/2 to antigen processing and presentation by MHC class I molecules |
| 41 | N00185 | KSHV MIR2 to cell surface molecule-endocytosis |
| 42 | N00155 | Autophagy-vesicle nucleation |
| 43 | N00177 | KSHV vBCL2 to autophagy-vesicle nucleation |
| 44 | N00156 | Autophagy-vesicle elongation |
| 45 | N00176 | KSHV vFLIP to autophagy-vesicle elongation |
| 46 | N00066 | MDM2-p21-Cell cycle G1/S |
| 47 | N00167 | KSHV vIRF1/3 to p21-cell cycle G1/S |
| 48 | N00169 | KSHV LANA to p21-cell cycle G1/S |
| 49 | N00168 | KSHV vCyclin to cell cycle G1/S |
| 50 | N00170 | KSHV LANA to cell cycle G1/S |
| 51 | N00146 | Crosstalk between extrinsic and intrinsic apoptotic pathways |
| 52 | N00166 | KSHV vFLIP to crosstalk between extrinsic and intrinsic apoptotic pathways |
| 53 | N00164 | KSHV vBCL2 to crosstalk between extrinsic and intrinsic apoptotic pathways |
| 54 | N00165 | KSHV vIAP to crosstalk between extrinsic and intrinsic apoptotic pathways |